Abstract
Background: The use of effective contraceptive methods must be encouraged among adolescents, not only to prevent unintended pregnancies but also to promote the sexual health and well-being of these young people. In effect, hormonal contraceptives offer several benefits beyond prevention of pregnancy to every woman, in particular to adolescents (e.g., dysmenorrhea, irregular bleeding, hirsutism, acne); moreover, they can be a targeted therapy for some gynecological diseases (e.g., endometriosis, polycystic ovary syndrome), to ensure a better quality of life.
Objective: The purpose of this article is to review the different formulations of COCs for adolescent and young adult women, and analyze their efficacy, safety, and benefits of specific pathological conditions.
Methods: We screened published literature on PubMed/MEDLINE and Scopus, using as keywords “oral contraceptive” in adolescent and young adult women. We included only articles in English about the COCs, different regimens and formulations.
Results: Our literature analysis allows us to underline the important role of COC not only as birth control method, but also as valid treatments for gynecological disorders related to hormonal fluctuations (e.g., dysmenorrhea, irregular bleeding, hirsutism, acne) and pathological diseases, such as polycystic ovarian syndrome (PCOS), endometriosis, with a preventive role for fertility preservation and pelvic inflammatory disease.
Conclusion: Adequate, care and competent counseling is the key to achieve good compliance of young women with contraception. Through the “GATHER” method suggested by WHO, health care providers should first evaluate the balance between benefits and risks of hormonal treatment, create an appropriate safety profile and then recommend COC prescription in adolescent and young women.
Keywords: Adolescence, contraception, pregnancy, complications, counseling, sexual health.
Graphical Abstract
[1]
Truehart A, Whitaker A. Contraception for the adolescent patient. Obstet Gynecol Surv 2015; 70: 263-73.
[2]
Pires R, Araújo-Pedrosa A, Pereira J, Canavarro MC. Preventing adolescent pregnancy: Biological, social, cultural, and political influences on age at first sexual intercourse. J Prim Prev 2014; 35: 239-54.
[3]
Skouby SO. Contraceptive use and behavior in the 21st century: A comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2010; 15(Suppl. 2): S42-53.
[4]
Ott MA, Sucato GS. Committee on Adolescence Contraception for adolescents. Pediatrics 2014; 134: e1257-81.
[5]
Buston K, Williamson L, Hart G. Young women under 16 years with experience of sexual intercourse: Who becomes pregnant? J Epidemiol Community Heal 2007; 61: 221-5.
[6]
Sedgh G, Finer LB, Bankole A, Eilers MA, Singh S. Adolescent pregnancy, birth, and abortion rates across countries: Levels and recent trends. J Adolesc Heal 2015; 56: 223-30.
[7]
Bezemer ID, Verhamme KMC, Gini R, et al. Use of oral contraceptives in three European countries: A population-based multi-database study. Eur J Contracept Reprod Heal Care 2016; 21: 81-7.
[8]
Kavanaugh ML, Jerman J, Ethier K, Moskosky S. Meeting the contraceptive needs of teens and young adults: Youth-friendly and long-acting reversible contraceptive services in U.S. family planning facilities. J Adolesc Health 2013; 52: 284-92.
[9]
Bitzer J. Oral contraceptives in adolescent women. Best Pract Res Clin Endocrinol Metab 2013; 27: 77-89.
[10]
Chiofalo B, Laganà AS, Imbesi G, et al. Is oral contraceptive-induced headache dependent on patent foramen ovale? Clinical dynamics, evidence-based hypothesis and possible patient-oriented management. Med Hypotheses 2016; 94: 86-8.
[11]
Golobof A, Kiley J. The Current status of oral contraceptives: Progress and recent innovations. Semin Reprod Med 2016; 34: 145-51.
[12]
Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med 2011; 8: 2841-50.
[13]
Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception 2004; 69: 237-40.
[14]
Caruso S, Cianci S, Malandrino C, Cicero C, Lo Presti L, Cianci A. Quality of sexual life of women using the contraceptive vaginal ring in extended cycles: Preliminary report. Eur J Contracept Reprod Health Care 2014; 19: 307-14.
[15]
Caruso S, Cianci S, Malandrino C, Cicero C, Lo Presti L, Cianci A. Hyperandrogenic women treated with a continuous-regimen oral contraceptive. Eur J Obstet Gynecol Reprod Biol 2013; 171: 307-10.
[16]
Upadhya KK, Santelli JS, Raine-Bennett TR, Kottke MJ, Grossman D. Over-the-counter access to oral contraceptives for adolescents. J Adolesc Heal 2017; 60: 634-40.
[18]
Caruso S, Malandrino C, Cicero C, Ciancio F, Cariola M, Cianci A. Quality of sexual life of women on oral contraceptive continued-regimen: Pilot study. J Sex Med 2013; 10: 460-6.
[19]
Caruso S, Iraci Sareri M, Agnello C, et al. Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: Comparison between two regimens containing 3 mg drospirenone and 20 µg ethinyl estradiol. J Sex Med 2011; 8: 1478-85.
[20]
De Leo V, Caruso S, Scolaro V, Cianci A. [Low dose oral contraceptives: 30 microg are still used?]. Minerva Ginecol 2009; 61: 453-8.
[21]
Caruso S, Rugolo S, Agnello C, Romano M, Cianci A. Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. J Sex Med 2009; 6: 3376-84.
[22]
Woodhams EJ, Gilliam M. In the Clinic. Contraception. Ann Intern Med 2012; 157: ITC4-1-ITC4-15. quiz ITC4-16
[23]
Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005; 72: 19-23.
[24]
Caruso S, Serra A, Maiolino L, et al. Cytological aspects of the nasal respiratory epithelium in reproductive-age women taking oral contraceptives. Eur J Contracept Reprod Health Care 2006; 11: 250-7.
[25]
Caruso S, Serra A, Grillo C, Agnello C, Di Mari L, Cianci A. Prospective study on the cytological aspects of the nasal respiratory epithelium in premenopausal women taking 30 mcg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2008; 77: 344-9.
[26]
Brynhildsen J. Combined hormonal contraceptives: Prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf 2014; 5: 201-13.
[28]
Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Heal Care 2018; 23: 24-31.
[29]
Tepper NK, Marchbanks PA, Curtis KMUS. selected practice recommendations for contraceptive use, 2013. J Womens Health (Larchmt) 2014; 23: 108-11.
[30]
Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected practice recommendations for contraceptive use, 2016. MMWR 2016; 65: 1-66.
[31]
Maguire K, Westhoff C. The state of hormonal contraception today: Established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011; 205: S4-8.
[32]
Motta T, Laganà AS, Valenti G, et al. [Differential diagnosis and management of abnormal uterine bleeding in adolescence]. Minerva Ginecol 2017; 69: 618-30.
[33]
Powell A. Choosing the right oral contraceptive pill for teens. Pediatr Clin North Am 2017; 64: 343-58.
[34]
Appleton SM. Premenstrual syndrome: Evidence-based evaluation and treatment. Clin Obstet Gynecol 2018; 61: 52-61.
[35]
Machado RB, Pompei Lde M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: A review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7: 19-30.
[36]
Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746-54.
[37]
Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; (7): CD004425.
[38]
Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: A systematic review. Contraception 2012; 86: 606-21.
[39]
Scholes D, Ichikawa L, LaCroix AZ, et al. Oral contraceptive use and bone density in adolescent and young adult women. Contraception 2010; 81: 35-40.
[40]
WHO WHO statement on hormonal contraception and bone health. Relev Epidemiol Hebd 2005; 80: 302-4.
[41]
Lopez LM, Chen M, Mullins Long S, Curtis KM, Helmerhorst FM. Steroidal contraceptives and bone fractures in women: Evidence from observational studies. Cochrane Database Syst Rev 2015; (8): CD009849.
[42]
Laganà AS, Vergara D, Favilli A, et al. Epigenetic and genetic landscape of uterine leiomyomas: A current view over a common gynecological disease. Arch Gynecol Obstet 2017; 296: 855-67.
[43]
Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: A meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet 2013; 288: 139-48.
[44]
Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: A prospective study. Am J Epidemiol 2004; 159: 113-23.
[45]
Westhoff C, Britton JA, Gammon MD, Wright T, Kelsey JL. Oral contraceptive and benign ovarian tumors. Am J Epidemiol 2000; 152: 242-6.
[46]
Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab 2013; 11: 41-7.
[48]
Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999; 82: 191-6.
[49]
Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: Cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 2007; 335: 651.
[50]
Laganà AS, Sofo V, Vitale SG, Triolo O. Epithelial ovarian cancer inherent resistance: May the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecol Oncol Rep 2016; 18: 57-8.
[51]
Ferranti G, Prosperi Porta R, La Rosa VL, Vitale SG, Laganà AS. [Reflections on treatments for infertility and the possible occurrence of ovarian carcinomas.]. Recenti Prog Med 2017; 108: 136-40.
[52]
Vessey M, Yeates D. Oral contraceptive use and cancer: Final report from the Oxford–Family Planning Association contraceptive study. Contraception 2013; 88: 678-83.
[53]
Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: A meta-analysis. Expert Rev Anticancer Ther 2011; 11: 1197-207.
[54]
Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 127: 442-51.
[55]
Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. Impact of endometriosis on quality of life and psychological well-being. J Psychosom Obstet Gynaecol 2017; 38: 317-9.
[56]
Caruso S, Agnello C, Malandrino C, Lo Presti L, Cicero C, Cianci S. Do hormones influence women’s sex? Sexual activity over the menstrual cycle. J Sex Med 2014; 11: 211-21.
[57]
Sauvan M, Chabbert-Buffet N, Geoffron S, Legendre G, Wattier J-M, Fernandez H. [Management of painful endometriosis in adolescents: CNGOF-HAS Endometriosis Guidelines]. Gynécol Obstét Fertil Sénol 2018; 46: 264-6.
[58]
Benagiano G, Guo SW, Puttemans P, Gordts S, Brosens I. Progress in the diagnosis and management of adolescent endometriosis: An opinion. Reprod Biomed Online 2018; 36: 102-14.
[59]
Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. Comment on: “Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference. J Psychosom Obstet Gynecol 2017; 38: 81-2.
[60]
La Rosa VL, Valenti G, Sapia F, Gullo G, Rapisarda AMC. Psychological impact of gynecological diseases: The importance of a multidisciplinary approach. Ital J Gynaecol Obstet 2018; 30: 23-6.
[61]
Vitale SG, Petrosino B, La Rosa VL, Rapisarda AMC, Laganà AS. A systematic review of the association between psychiatric disturbances and endometriosis. J Obstet Gynaecol Can 2016; 38: 1079-80.
[62]
Laganà AS, La Rosa VL, Rapisarda AMC, et al. Anxiety and depression in patients with endometriosis: Impact and management challenges. Int J Womens Health 2017; 9: 323-30.
[63]
Laganà AS, La Rosa V, Petrosino B, Vitale SG. Comment on “Risk of developing major depression and anxiety disorders among women with endometriosis: A longitudinal follow-up study.”. J Affect Disord 2017; 208: 672-3.
[64]
Laganà AS, Condemi I, Retto G, et al. Analysis of psychopathological comorbidity behind the common symptoms and signs of endometriosis. Eur J Obstet Gynecol Reprod Biol 2015; 194: 30-3.
[65]
Vetvicka V, Laganà AS, Salmeri FM, et al. Regulation of apoptotic pathways during endometriosis: From the molecular basis to the future perspectives. Arch Gynecol Obstet 2016; 294: 897-904.
[66]
Machairiotis N, Stylianaki A, Dryllis G, et al. Extrapelvic endometriosis: A rare entity or an under diagnosed condition? Diagn Pathol 2013; 8: 194.
[67]
Maniglio P, Ricciardi E, Meli F, et al. Catamenial pneumothorax caused by thoracic endometriosis. Radiol Case Rep 2018; 13: 81-5.
[68]
Butticè S, Laganà AS, Mucciardi G, et al. Different patterns of pelvic ureteral endometriosis. What is the best treatment? Results of a retrospective analysis. Arch Ital Urol Androl 2016; 88: 266-9.
[69]
Laganà AS, Vitale SG, Trovato MA, et al. Full-thickness excision versus shaving by laparoscopy for intestinal deep infiltrating endometriosis: Rationale and potential treatment options. Biomed Res Int 2016; 2016: 3617179.
[70]
Vitale SG, La Rosa VL, Vitagliano A, et al. Sexual function and quality of life in patients affected by deep infiltrating endometriosis: Current evidence and future perspectives. J Endometr Pelvic Pain Disord 2017; 9: 270-4.
[71]
Montanari G, Di Donato N, Benfenati A, et al. Women with deep infiltrating endometriosis: Sexual satisfaction, desire, orgasm, and pelvic problem interference with sex. J Sex Med 2013; 10: 1559-66.
[72]
Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. Endometriosis and infertility: The impact on quality of life and mental health. J Endometr Pelvic Pain Disord 2017; 9: 112-5.
[73]
Laganà AS, Vitale SG, Granese R, et al. Clinical dynamics of Dienogest for the treatment of endometriosis: From bench to bedside. Expert Opin Drug Metab Toxicol 2017; 13: 593-6.
[74]
Laganà AS, Vitale SG, Salmeri FM, et al. Unus pro omnibus, omnes pro uno: A novel, evidence-based, unifying theory for the pathogenesis of endometriosis. Med Hypotheses 2017; 103: 10-20.
[75]
Laganà AS, Salmeri FM, Vitale SG, Triolo O, Götte M. Stem cell trafficking during endometriosis: May epigenetics play a pivotal role? Reprod Sci 2018; 25: 978-9.
[76]
Laganà AS, Salmeri FM, Triolo O, Vitale SG, Granese R, Sofo V. Comments on “rhTNFR:Fc suppresses the development of endometriosis in a mouse model by downregulating cell proliferation and invasiveness”. Reprod Sci 2018; 25: 983-4.
[77]
Maniglio P, Ricciardi E, Laganà AS, Triolo O, Caserta D. Epigenetic modifications of primordial reproductive tract: A common etiologic pathway for Mayer-Rokitansky-Kuster-Hauser Syndrome and endometriosis? Med Hypotheses 2016; 90: 4-5.
[78]
Laganà AS, Triolo O, Salmeri FM, et al. Natural Killer T cell subsets in eutopic and ectopic endometrium: A fresh look to a busy corner. Arch Gynecol Obstet 2016; 293: 941-9.
[79]
Vitale SG, Capriglione S, Peterlunger I, et al. The role of oxidative stress and membrane transport systems during endometriosis: A fresh look at a busy corner. Oxid Med Cell Longev 2018; 2018: 7924021.
[80]
Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 2016; 39: 923-31.
[81]
Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest 2015; 38: 1211-8.
[82]
Spritzer PM, Motta AB. Adolescence and polycystic ovary syndrome: Current concepts on diagnosis and treatment. Int J Clin Pract 2015; 69: 1236-46.
[83]
Chiofalo B, Laganà AS, Palmara V, et al. Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype? Med Hypotheses 2017; 105: 1-3.
[84]
Della Corte L, La Rosa VL, Rapisarda AMC, et al. Current evidences and future perspectives on patient-oriented treatments for polycystic ovary syndrome: An overview. Ital J Gynaecol Obstet 2018; 30: 7-20.
[85]
Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015; 136: 1154-65.
[86]
Cianci A, Panella M, Fichera M, Falduzzi C, Bartolo M, Caruso S. D-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol 2015; 31: 483-6.
[87]
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
[88]
Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-45.
[89]
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and pcos society disease state clinical review: Guide to the best practices in the evaluation and treatment of Polycystic Ovary Syndrome - Part 2. Endocr Pract 2015; 21: 1415-26.
[90]
De Leo V, Di Sabatino A, Musacchio MC, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010; 82: 276-80.
[91]
Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: The effect of inositol and metformin. J Assist Reprod Genet 2014; 31: 1269-76.
[92]
La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: A retrospective study. Gynecol Endocrinol 2015; 31: 52-6.
[93]
Laganà AS, Rossetti P, Sapia F, et al. Evidence-based and patient-oriented inositol treatment in polycystic ovary syndrome: Changing the perspective of the disease. Int J Endocrinol Metab 2017; 15: e43695.
[94]
Laganà AS, Sapia F, La Rosa VL, Vitale SG. Comment on “Inositols: From physiology to rational therapy in gynecological clinical practice.”. Expert Opin Drug Metab Toxicol 2016; 12: 1527.
[95]
Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet 2015; 291: 1181-6.
[96]
Laganà AS, Rossetti P, Buscema M, et al. Metabolism and ovarian function in PCOS women: A therapeutic approach with inositols. Int J Endocrinol 2016; 2016: 6306410.
[97]
Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM. Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: State-of-the-art and future perspectives. Gynecol Endocrinol 2016; 32: 431-8.
[98]
Gulino FA, Leonardi E, Marilli I, et al. Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: In vivo study. Gynecol Endocrinol 2016; 32: 65-8.
Article Metrics
51
9